Marketing Applications, Product Launches, Commencement of Studies, Collaborations, and Release of Funding - Research Report on

      Marketing Applications, Product Launches, Commencement of Studies,
   Collaborations, and Release of Funding - Research Report on Biogen Idec,
                  Illumina, Santarus, Celsion, and BioCryst

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 24, 2013

NEW YORK, July 24, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), Illumina, Inc. (NASDAQ: ILMN), Santarus, Inc.
(NASDAQ: SNTS), Celsion Corporation (NASDAQ: CLSN), and BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Biogen Idec Inc. Research Report

On July 19, 2013, Biogen Idec Inc. (Biogen Idec) announced that the US Food
and Drug Administration and the European Medicines Agency have accepted the
marketing applications for the review of PLEGRIDY (peginterferon beta-1a), the
Company's pegylated subcutaneous injectable candidate for relapsing forms of
multiple sclerosis (MS). According to the Company, the regulatory applications
included positive one-year results from the two-year global Phase 3 ADVANCE
study. In that study, data demonstrated PLEGRIDY met all primary and secondary
endpoints by significantly reducing disease activity including relapses,
disability progression and brain lesions compared to placebo, and showed
favorable safety and tolerability profiles at one year. The Full Research
Report on Biogen Idec Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/BIIB]

Illumina, Inc. Research Report

On July 18, 2013, Illumina Inc. (Illumina) announced the availability of its
Phasing Analysis Service created by the Company's FastTrack Services lab
through the Illumina Genome Network (IGN). According to Illumina, the new
sample-to-answer service delivers human whole-genome phase information, thus
empowering gene mapping studies with a more comprehensive view of genomic
variation. The Company further said that with Phase data, researchers can
better understand the effect of genotype on phenotype and variant interaction
within a gene. Christian Henry, Senior Vice President and General Manager of
Illumina's Genomic Solutions business, said, "Customers who participated in
the beta testing used the service for a diverse range of applications, from
human population studies to the identification of variants causing rare
disease. Early customer feedback has been overwhelmingly positive." According
to the Company, the new Phasing Analysis Service is available for immediate
ordering and as an add-on to the IGN Whole-Genome Analysis Service, which
delivers results within twelve weeks.The Full Research Report on Illumina,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/ILMN]

Santarus, Inc. Research Report

On July 18, 2013, Santarus, Inc. (Santarus) announced the completion of
enrollment in the CONTRIBUTE clinical study, which is designed to evaluate the
incremental benefit of adding UCERIS (budesonide) extended release 9mg tablets
to oral aminosalicylate (5-ASA) therapy for the induction of clinical
remission in adult patients with active, mild to moderate ulcerative colitis.
According to the Company UCERIS is currently approved in the US for the
induction of remission in patients with active, mild to moderate ulcerative
colitis. 509 patients were enrolled in the CONTRIBUTE study, a multicenter,
randomized, double-blind placebo controlled clinical trial. According to
Santarus, the primary endpoint of the study is clinical remission, which is
defined as a score of 0 for both rectal bleeding and stool frequency on the
Ulcerative Colitis Disease Activity Index (UCDAI) scale. The Full Research
Report on Santarus, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/SNTS]

Celsion Corporation Research Report

On July 19, 2013, Celsion Corporation (Celsion) and Zhejiang Hisun
Pharmaceutical Company Ltd. (Hisun) announced that they have entered into a
Memorandum of Understanding to pursue ongoing collaborations for the continued
clinical development of ThermoDox as well as the technology transfer relating
to the commercial manufacture of ThermoDox for the greater China territory.
According to the Company, the key provisions of the collaboration include:
Hisun will provide Celsion with non-dilutive financing and the investment
necessary to complete the technology transfer of its proprietary manufacturing
process and the production of registration batches for China, Hisun will
collaborate with Celsion around the clinical and regulatory approval
activities for ThermoDox as well as other liposomal formulations with the
China state Food and Drug Administration, and Hisun will be granted a right
first offer for a commercial license to ThermoDox for the sale and
distribution of ThermoDox in the greater China territory. Michael H. Tardugno,
Celsion's President and CEO, said, "We are pleased to announce our expanded
collaboration with Celsion for the continued development of ThermoDox to treat
HCC to patients in China, the world's largest market. China is one of the
countries with the highest HCC incidence and mortality and, up until now,
there has not been any standard of care for treating intermediate HCC in
China." The Full Research Report on Celsion Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/CLSN]

BioCryst Pharmaceuticals, Inc. Research Report

On July 11, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced that the
Biomedical Advanced Research and Development Authority (BARDA/HHS) has
released funding under the current $234.8 million contract to enable
completion of a New Drug Application (NDA) filing for intravenous peramivir.
According to BioCryst, peramivir is a potent, intravenously administered
investigational anti-viral agent that quickly delivers high plasma
concentrations to the site of infection. The Company further stated that it
has reached an agreement with US Food and Drug Administration in relation to
all the requirements for a complete NDA submission. BioCryst expects to submit
the peramivir NDA by the end of 2013. The Full Research Report on BioCryst
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/BCRX]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Investors' Reports

Contact: InvestorsReports.com Kristi Saunders +1-315-982-6420 (North America)